NCT04294225View on ClinicalTrials.gov

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Early-Stage Breast CarcinomaInvasive Breast CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
DRUG

Anastrozole

Given PO

DRUG

Letrozole

Given PO

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT04294225 - Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter